Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.3.2013

Effects of Two Chemotherapy Regimens, Anthracycline-based and CMF, on Breast Cancer Disease Free Survival in the Eastern Mediterranean Region and Asia: A Meta-Analysis Approach for Survival Curves  

Zare, Najaf (Department of Biostatistics, Research Center of Infertility, Shiraz University of Medical Sciences)
Ghanbari, Saeed (Department of Biostatistics, Research Center of Infertility, Shiraz University of Medical Sciences)
Salehi, Alireza (Department of Biostatistics, Faculty of Medical Science, Shiraz University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.3, 2013 , pp. 2013-2017 More about this Journal
Abstract
Background: To compare the effects of two adjuvant chemotherapy regimens, anthracycline-based and cyclophosphamide, methotrexate, fluorourical (CMF) on disease free survival for breast cancer patients in the Eastern Mediterranean region and Asia. Methods: In a systematic review with a multivariate mixed model meta-analysis, the reported survival proportion at multiple time points in different studies were combined. Our data sources were studies linking the two chemotherapy regimens on an adjuvant basis with disease free survival published in English and Persian in the Eastern Mediterranean region and Asia. All survival curves were generated with Graphdigitizer software. Results: 14 retrospective cohort studies were located from electronic databases. We analyzed data for 1,086 patients who received anthracycline-based treatment and 1,109 given CMF treatment. For determination of survival proportions and time we usesb the transformation Ln (-Ln(S)) and Ln (time) to make precise estimations and then fit the model. All analyses were carried out with STATA software. Conclusions: Our findings showed a significant efficacy of anthracycline-based adjuvant therapy regarding disease free survival of breast cancer. As a limitation in this meta-analysis we used studies with different types of anthracycline-based regimens.
Keywords
Meta-analysis; disease free survival curve; multivariate mixed model; adjuvant chemotherapy regimens;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Al-Moundhri M, Al-Bahrani B, Pervez I, et al (2004).The outcome of treatment of breast cancer in a developing country-oman. The Breast, 13, 139-45.   DOI   ScienceOn
2 Arends L.R, Myriam Hunink M.G, Stijnen Th (2008).Metaanalysis of summary survival curve data. Statistics in Med, 27, 4381-96.   DOI   ScienceOn
3 American Cancer Society (2010).Breast cancer facts & figures .Atlanta; American Cancer Society, Inc.
4 Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B (2010). Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Hlth J, 16, 1032-8.
5 Abbas H, Elyamany A, Salem M, et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35-42.   DOI   ScienceOn
6 Wang SH, Yanxia S, Yuan ZH, et al (2011). Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol, 11, 9964-72.
7 Yan PW, Huang XE (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/ cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
8 Zhang J, Yan LIU (2008). HER2 over-expression and response to different chemotherapy regimens in breast cancer. J Zhejinang University Science, 9, 5-9.   DOI   ScienceOn
9 Brunner, Suddarth's (2008). Textbook of medical-surgical nursing. 11th Edition, chapter 1.
10 Dear KBG (1994). Iterative generalized least squares for metaanalysis of survival data at multiple times. Biometrics, 50, 989-1002.   DOI   ScienceOn
11 Duolao W, Ameet B, Felicity C (2006). A Practical Guide to Design, Analysis, and Reporting Clinical Trials. London Remedica, chapter 38.
12 Dersimonian R, Kacher R (2007). Random-effect model for meta-analysis of clinical trials: an update. Contemp Clinical Trials, 28, 105-14.   DOI   ScienceOn
13 Di Leo A, Desmedt C, Bartlett J, et al (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol, 12, 1134-42.   DOI   ScienceOn
14 Faradmal J, Kazemnejad A, Khoda BR, Hajizade E, Gohari MR (2010). Comparing three adjuvant chemotherapy regimens after modified radical mastectomy in breast cancer patients using log-logistic model. Sci J Semnan Univ Med Sci, 11, 279-86.
15 Hedges LV, Vevea JL (1998). Fixed and random effects model in meta-analysis. Psychological Methods, 3, 486-504.   DOI   ScienceOn
16 Ismaili N, Mellas N, Masbah O, et al (2009). Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol, 4, 12-25.   DOI   ScienceOn
17 Ismaili N, Elmajjaoui S, Lalya I, et al (2010). Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes, 3, 247-57.
18 Katalinic A, Pritzkuleit R, Waldmann A (2009). Recent trends in breast cancer incidence and mortality in Germany. Breast Care, 4, 75-80.   DOI   ScienceOn
19 Kleinbaum D (2004). Survival analysis a self- learning text. Springer.
20 Kuru B, Camlibel M, Dine S, et al (2005). A comparison of the outcomes of non-randomized chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer Res, 3, 363-71.
21 Kim K, Chie EK, Han W, et al (2011).Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Tumori, 97, 280-5.
22 Lian-Fang Li, Xiao-Jing Xu, Zhao Y, et al (2008). Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat, 113, 231-7.
23 Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in iran: an epidemiological review. The Breast J, 13, 383-91.   DOI   ScienceOn
24 Sakakibara M, Nagashima T, Kadowaki M, et al (2009). Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol, 16, 2470-8.   DOI
25 Wong ZW, Ang PCS (2008). Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in asian women with metastatic breast cancer. The Breast, 17, 517-22.   DOI   ScienceOn